SurvivorNet Staff

SurvivorNet Staff


From PSMA PET to Triplet Therapy: A Prostate Cancer Expert’s Decision Path for Rising PSA Play
From PSMA PET to Triplet Therapy: A Prostate Cancer Expert’s Decision Path for Rising PSA
By SurvivorNet Staff
Chemo, Pluvicto or a Targeted Agent? How One MSK Expert Picks the Third Drug in Newly Diagnosed Metastatic Prostate Cancer Play
Chemo, Pluvicto or a Targeted Agent? How One MSK Expert Picks the Third Drug in Newly Diagnosed Metastatic Prostate Cancer
By SurvivorNet Staff
‘They’ll Be Able to See Their Kids Grow’: Neurosurgeon Dr. Yoshua Esquenazi on the New Era in IDH-Mutant Glioma Play
‘They’ll Be Able to See Their Kids Grow’: Neurosurgeon Dr. Yoshua Esquenazi on the New Era in IDH-Mutant Glioma
By SurvivorNet Staff
Personalized mRNA Vaccine + Keytruda Combo Marks Significant Advance in High‑Risk Melanoma and May Reduce Melanoma Recurrence
Personalized mRNA Vaccine + Keytruda Combo Marks Significant Advance in High‑Risk Melanoma and May Reduce Melanoma Recurrence
By SurvivorNet Staff
FDA Expands Trodelvy’s Approval to First-Line Metastatic Triple-Negative Breast Cancer Play
FDA Expands Trodelvy’s Approval to First-Line Metastatic Triple-Negative Breast Cancer
By SurvivorNet Staff
Glioma Experts Weigh In: How to Manage Progression in IDH Mutant Gliomas as the Role of IDH Inhibition Expands Play
Glioma Experts Weigh In: How to Manage Progression in IDH Mutant Gliomas as the Role of IDH Inhibition Expands
By SurvivorNet Staff
MHQ Clinical Intelligence. Another Opinion. When You Need It. Before the Next Patient. Play
MHQ Clinical Intelligence. Another Opinion. When You Need It. Before the Next Patient.
By SurvivorNet Staff
Optune Pax: A Meaningful Increase In OS For Localized, Advanced Pancreatic Cancer
Optune Pax: A Meaningful Increase In OS For Localized, Advanced Pancreatic Cancer
By SurvivorNet Staff
Bridging the Gap: Making Breakthrough Follicular Lymphoma Treatments Accessible Beyond Major Cancer Centers
Bridging the Gap: Making Breakthrough Follicular Lymphoma Treatments Accessible Beyond Major Cancer Centers
By SurvivorNet Staff
Dr. Daniel Spratt On Rethinking Frontline Strategy in High-Risk Prostate Cancer: Why Radioligand Therapy May Belong Earlier Play
Dr. Daniel Spratt On Rethinking Frontline Strategy in High-Risk Prostate Cancer: Why Radioligand Therapy May Belong Earlier
By SurvivorNet Staff
FDA Approves Sacituzumab Govitecan for First Line for Advanced TNBC, a Move Breast Oncologist Dr. Kevin Punie Says ‘Improves PFS & Quality of Life Upfront’ Play
FDA Approves Sacituzumab Govitecan for First Line for Advanced TNBC, a Move Breast Oncologist Dr. Kevin Punie Says ‘Improves PFS & Quality of Life Upfront’
By SurvivorNet Staff
Cornell’s Dr. Manish Shah On The Importance of Biomarker Testing in HER2-Driven Gastroesophageal Cancer
Cornell’s Dr. Manish Shah On The Importance of Biomarker Testing in HER2-Driven Gastroesophageal Cancer
By SurvivorNet Staff
Cornell’s Dr. Manish Shah On Zanidatamab’s Evolving Role In Gastroesophageal Junction Cancer
Cornell’s Dr. Manish Shah On Zanidatamab’s Evolving Role In Gastroesophageal Junction Cancer
By SurvivorNet Staff
Leading Oncologist Rings the Alarm Bell: “We Have a Crisis in Life-Saving Access to CAR T-Cell Therapy” Play
Leading Oncologist Rings the Alarm Bell: “We Have a Crisis in Life-Saving Access to CAR T-Cell Therapy”
By SurvivorNet Staff
Dr. Tiffany Tanaka Talks Benefits Of All-Oral Inqovi Regimen & Broadening Low-Intensity Treatment Options For AML Play
Dr. Tiffany Tanaka Talks Benefits Of All-Oral Inqovi Regimen & Broadening Low-Intensity Treatment Options For AML
By SurvivorNet Staff
Mirvetuximab Soravtansine (Elahere) Report Card: Three Years Of Real-World Data Play
Mirvetuximab Soravtansine (Elahere) Report Card: Three Years Of Real-World Data
By SurvivorNet Staff
Landmark MATTERHORN Study: Lead Investigator Dr. Yelena Y. Janjigian On What It Means For Practice Play
Landmark MATTERHORN Study: Lead Investigator Dr. Yelena Y. Janjigian On What It Means For Practice
By SurvivorNet Staff
A Potential Paradigm Shift in CAR-T: inMMyCAR Trial Play
A Potential Paradigm Shift in CAR-T: inMMyCAR Trial
By SurvivorNet Staff
The 30th Society For Neuro-Oncology Annual Meeting Highlights Play
The 30th Society For Neuro-Oncology Annual Meeting Highlights
By SurvivorNet Staff
ASTRO 2025 Event: The New Era In Glioma Treatment, Racing To Understand Targeted Therapy & Making Better Decisions For Patients Play
ASTRO 2025 Event: The New Era In Glioma Treatment, Racing To Understand Targeted Therapy & Making Better Decisions For Patients
By SurvivorNet Staff

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider